Stockholm, May 1st, 2020 – Swedish biotechnology company CARTANA today announced the launch of a new range of In Situ Sequencing (ISS) reagent kits designed to increase the efficiency and enable ISS on virtually any tissue sample. Users will be able to analyse either fresh/fixed frozen or FFPE samples and rapidly create single cell gene expression maps of up to 600 genes. The new ISS technology opens up for a broad variety of research areas like immuno-oncology or any other cancer field. CARTANA has already been successful in the neuroscience field and has recently been selected as a platform technology provider for 3 major Horizon 2020 Human Cell Atlas projects. These new products widen the applications areas making CARTANA an even more attractive technology provider for drug discovery and academic research.
Performances of the HS Library Preparation kit on mouse FFPE tissue samples
The new kit products contain improved probing and sequencing technologies and come with easy-to-follow protocols for library preparation and sequencing, respectively. The “HS Library Preparation Kit” is used to probe directly up to 600 RNA targets without the need for cDNA synthesis and generates barcoded In Situ Sequencing libraries with higher efficiency compared to the previous cDNA-based library preparation approach, initially published in 2013 (Ke, et al. 2013). “Our new HS library preparation kit has a strongly increased sensitivity with around 5 to 10 times more counts than our previous cDNA-based version”, says Malte Kühnemund, VP R&D at CARTANA. Furthermore, the new “ISS kit” sequences the barcodes in the libraries directly in situ, with enhanced signal-to-noise ratio and specificity compared to the previous state-of-the-art ISS technology The new ISS kit contains 6 sequencing cycles and decodes up to 600 barcodes using a standard fluorescent microscope. “The robust chemistry and easy-to-use protocol enable a broad adoption of ISS to virtually any laboratory equipped with a fluorescent microscope. With these new kits we expect that increasing number of labs will start to establish the Cartana technology in house.”, says Mårten Winge, CEO of CARTANA. Both products are available from May 1st 2020. Gene panels with genes for several disease areas are being developed, but customized genes are also available for specific areas of interest. Tissue samples from all organs and all species are compatible with the kits, including fresh/fixed frozen or FFPE samples.
For more information, please contact:
Mårten Winge, CEO of CARTANA
Email: [email protected]
CARTANA is a privately owned Swedish biotech that spun out of the Science for Life Laboratory in 2017. The company is developing in situ RNA sequencing technology that is based on research originally developed in Mats Nilsson’s laboratory at SciLifeLab, Stockholm, Sweden. For more information, visit https://www.cartana.se/ where the technology is further described.